Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | TP53 | P04637 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | MITF | O75030 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nifuratel SCHEMBL153100 | 1.00 | HIF1A (0.68) | HIF1AKMT2AUSP2MAPK9LMNA | |
| Nifuratel SCHEMBL1649685 | 1.00 | HIF1A (0.68) | HIF1AKMT2AUSP2MAPK9LMNA | |
| Nifuratel SCHEMBL15375600 | 1.00 | HIF1A (0.68) | HIF1AKMT2AUSP2MAPK9LMNA | |
| Nifuratel SCHEMBL153098 | 1.00 | HIF1A (0.68) | HIF1AKMT2AUSP2MAPK9LMNA | |
| Nifuratel SCHEMBL16675657 | 1.00 | HIF1A (0.68) | HIF1AKMT2AUSP2MAPK9LMNA | |
| Nifuratel SCHEMBL15068213 | 1.00 | HIF1A (0.68) | HIF1AKMT2AUSP2MAPK9LMNA | |
| Nifuratel SCHEMBL28338979 | 0.99 | HIF1A (0.67) | HIF1AKMT2AUSP2MAPK9LMNA | |
| Nifuratel SCHEMBL28086242 | 0.93 | LMNA (0.70) | HIF1AKMT2AUSP2MAPK9LMNA | |
| Nifuratel SCHEMBL1237293 | 0.89 | HIF1A (0.56) | HIF1AKMT2AUSP2MAPK9LMNA | |
| Nifuratel SCHEMBL27952170 | 0.88 | HIF1A (0.55) | HIF1AKMT2AUSP2MAPK9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025439-A1 | DERIVATIVES OF NIFUROXAZIDE FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISORDERS AND NEURODEGENERATIVE DISEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-01-23 | — | — | US | claimed |
| EP-4440569-A1 | DERIVATIVES OF NIFUROXAZIDE FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISORDERS AND NEURODEGENERATIVE DISEASES | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2024-10-09 | — | — | EP | claimed |
| WO-2023099554-A1 | DERIVATIVES OF NIFUROXAZIDE FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISORDERS AND NEURODEGENERATIVE DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-06-08 | — | — | WO | claimed |
| US-20250025439-A1 | DERIVATIVES OF NIFUROXAZIDE FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISORDERS AND NEURODEGENERATIVE DISEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-01-23 | — | — | US | disclosed |
| EP-4440569-A1 | DERIVATIVES OF NIFUROXAZIDE FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISORDERS AND NEURODEGENERATIVE DISEASES | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2024-10-09 | — | — | EP | disclosed |
| CN-114685479-B | Oxazolidinone compound as well as preparation method and application thereof | 南方科技大学 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023099554-A1 | DERIVATIVES OF NIFUROXAZIDE FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISORDERS AND NEURODEGENERATIVE DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-06-08 | — | — | WO | disclosed |
| CN-217773308-U | Raw material extraction equipment for nifuratel production | 盐城凯利药业有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-114478510-B | Preparation method of nifuratel | 盐城凯利药业有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-114685479-A | Oxazolidinone compound and preparation method and application thereof | 南方科技大学 | 2022-07-01 | — | — | CN | disclosed |
| CN-114478510-A | Preparation method of nifuratel | 盐城凯利药业有限公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-2593796-A2 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | Auckland Uniservices Limited (NZ) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012008860-A2 | BACTERIAL NITROREDUCTASE ENZYMES AND METHODS RELATING THERETO | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-01-19 | — | — | WO | disclosed |
| CN-101676284-A | Preparation method of nifuratel with high purity | BEIJING D VENTUREPHARM TECHNOL | 2010-03-24 | — | — | CN | disclosed |
| CN-100516063-C | Production method of nifuratel | ZHIQIANG HAN (CN) | 2009-07-22 | — | — | CN | disclosed |
| CN-100506820-C | (S)-nifuratel, preparation method and application thereof | ZHIQIANG HAN (CN) | 2009-07-01 | — | — | CN | disclosed |
| CN-100479817-C | The use of Nifuratel for preparing medicine for treating oral cavity infection | MEN LILI (CN) | 2009-04-22 | — | — | CN | disclosed |
| CN-101037434-A | Production method of nifuratel | HAN ZHIQIANG (CN) | 2007-09-19 | — | — | CN | disclosed |
| CN-101037435-A | (S)-nifuratel, preparation method and application thereof | HAN ZHIQIANG (CN) | 2007-09-19 | — | — | CN | disclosed |
| CN-101019864-A | Nifuratel for treating oral cavity infection | MEN LILI (CN) | 2007-08-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025439-A1 | DERIVATIVES OF NIFUROXAZIDE FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISORDERS AND NEURODEGENERATIVE DISEASES | CHCHD6, IMMT, CHCHD3 | HIF1A 3030/4885KMT2A 3441/4885USP2 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.